RxDoctor Payments Data

Mohammad Khan, MD

Psychiatry · Plano, TXNPI 1528028032

Payments from drug & device makers

$16,374in general payments, 2019–2025

Across 143 payments — averaging $114.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$14K
  • Otsuka America Pharmaceutical, Inc.$554
  • Johnson & Johnson$394
  • Takeda Pharmaceuticals U.S.A., Inc.$329
  • Supernus Pharmaceuticals, Inc.$218
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$155
  • plus $950 from 16 others

What the payments were for

  • Speaking & faculty fees$2,20044%
  • Travel & lodging$461%
  • Food & beverage$2,78755%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,374 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$22,565
Medicare patients
35
Services billed
250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole11$23,108
Vilazodone Hcl24$1,773
Quetiapine Fumarate46$1,339
Buspirone Hcl47$823
Gabapentin21$712
Duloxetine Hcl31$688
Venlafaxine Hcl ErVenlafaxine Hcl15$674
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine15$447
Bupropion XlBupropion Hcl25$377
Risperidone31$350
Divalproex Sodium11$339
Trazodone Hcl20$328
Lamotrigine18$328
Lithium Carbonate ErLithium Carbonate26$318
Divalproex Sodium ErDivalproex Sodium12$317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$554$23,10811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →